Author(s): Prerana Musale, S. D. Mankar

Email(s): preranamusale145@gmail.com

DOI: 10.52711/2231-5675.2023.00031   

Address: Prerana Musale*, S. D. Mankar
Department of Quality Assurance Technique, Pravara Rural College of Pharmacy, Pravaranagar, Tal: Rahta, Dist: Ahmednagar 413737, India.
*Corresponding Author

Published In:   Volume - 13,      Issue - 3,     Year - 2023


ABSTRACT:
Quality by design is used to designing and developing a formulation and manufacturing process to ensure a predefined quality and this process to enhance capability of process and reduce product variability and defects by increasing product and process design understanding and control. According to guidelines of International conference on Harmonization, Q8, Q9, Q10 are the foundations of Quality by design. Q8 for Pharmaceutical development to design quality of product, Q9 for Quality risk management (QRM) to identify and minimize the risk, Q10 for Pharmaceutical quality system is a management system to give assurity of product quality. Elements of quality by design include Quality Target Product Profile [QTPP] is identify critical Quality Attributes [CQAs] of drug product, product design and identify Critical Material Attributes [CMAs], process design and identify Critical Process Parameters [CPPs], The Control strategy consists of the process and input material control and monitors the design space to identify the final product that ensures the desired quality, process capability and continued improvement. Design of experiment [DoE] is gain to maximum information from a minimum number of experiments and the FDA intimate significance of the quality by granting Process Analytical Technology [PAT] as a framework for brand new pharmaceutical development, manufacturing and the quality assurance. goal of PAT to enhance understanding, control and safety of the manufacturing process and principle of PAT is quality cannot be tested into final product it should be built in or should be by design. Analytical quality by design [AQbD] is also an inherent part of the product development control strategy beside with other parameters such as process parameters, material attributes, equipment operating conditions, in-process controls, and finished product specifications.


Cite this article:
Prerana Musale, S. D. Mankar. Quality by Design Approch Based in Analytical Method Validation. Asian Journal of Pharmaceutical Analysis. 2023; 13(3):190-6. doi: 10.52711/2231-5675.2023.00031

Cite(Electronic):
Prerana Musale, S. D. Mankar. Quality by Design Approch Based in Analytical Method Validation. Asian Journal of Pharmaceutical Analysis. 2023; 13(3):190-6. doi: 10.52711/2231-5675.2023.00031   Available on: https://ajpaonline.com/AbstractView.aspx?PID=2023-13-3-7


REFERENCE:
1.    Q9: Quality Risk Management. ICH Harmonized Tripartite Guidelines. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. 2006.
2.    Kalyan S, Vihar P. Quality By Design: Changing Outlook of Pharmaceutical Development, Int J Pharmaceutical Sci Res. 2019; 10(9): 4100–8.
3.    Woodcock J. The Concept of Pharmaceutical Quality. Am Pharm Rev. 2004; 7(6): 10–5.
4.    Bradley D, Bronwyn G. NIR Spectroscopy - Just One of Many Analytical Tools for PAT. Amer Pharm Rev. 2011; 3: 70-74.
5.    Frederick TM, Sarah D, Jason N, Peter JS. On-line FTIR Monitoring and Simultaneous Optimization of a Strecker Reaction Performed in a Laboratory Scale Flow-Through Reactor. Amer Pharm Rev. 2011; 14(7): 212-219.
6.    DPT Thought Leadership. Issue 11: 1st in a series
7.    FDA Guidance for Industry and Review Staff: Target Product Profile – A Strategic Development Process Tool (Draft Guidance).
8.    Q8 (R1): Pharmaceutical Development, Revision 1, ICH Harmonized Tripartite Guidelines, International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, 2007.
9.    Q8 (R1): Pharmaceutical Development, Revision 1, ICH Harmonized Tripartite Guidelines, International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. 2007.
10.    J.M. Juran A.B. Godfrey, Juran‟s Quality Handbook, 5 th Edition, 1988; 29.1.
11.    Juran JM: Juran on quality by design: The new steps for planning quality into goods and services. Free Press, 1992
12.    Q8 (R1): Pharmaceutical Development, Revision 1, ICH Harmonized Tripartite Guidelines, International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. 2007.
13.    Q9: Quality Risk Management. ICH Harmonized Tripartite Guidelines. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. 2006.
14.    Q10: Pharmaceutical Quality System, ICH Tripartite Guidelines. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. 2007.
15.    Q8 (R1): Pharmaceutical Development, Revision 1, ICH Harmonized Tripartite Guidelines, International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. 2007.
16.    Food and Drug Administration, Office of Generic Drugs White Paper on Questionbased Review: http://www.fda.gov/cder/ OGD/QbR.htm.
17.    ICH, Q8 (R2), Harmonized Tripartite Guideline, Pharmaceutical development, Proceedings of the International Conference on Harmonization, Geneva, August, 2009.
18.    Xavier CM, Basavaiah K. Implementation of quality by design for the development and validation of pioglitazone hydrochloride by RP-UPLC with application to formulated forms. ISRN Chromatography. 2012; 2012. 11 pages.
19.    Chatterjee S. QbD considerations for Anal Methods—FDA perspective. In: IFPAC Annual Meeting, Baltimore, MD: CMC Lead for QbD ONDQA/CDER/FDA; 2013.
20.    Delasko, J., Cocchetto, D. M., and Burke, L. B. (2005). Target product profile: beginning drug development with the end in mind. Update.
21.    Food and Drug Administration CDER. (2007). Draft Guidance for Industry and Review Staff: Target Product Profile- A Strategic Development Tool (March 2007).
22.    Food and Drug Administration Office of Generic Drugs. (2006). Model Quality Overall Summaryfor IR Product, http://www.fda.gov/cder/ogd/OGD_Model-QoS_IR_Product.pdf (Accessed March 31, 2006).
23.    Patil, A. S., and Pethe, A. M. (2013). Quality by Design (QbD): A new concept for development of quality pharmaceuticals. International Journal of Pharmaceutical Quality Assurance, 4(2), 13-19.
24.    Nagar, M., Panwar, K. S., Chopra, V. S., Bala, I., and Trivedi, P. Quality by design: A systematic approach to pharmaceutical development. Der Pharmacia Lettre. 2010; 2(2): 111- 130.
25.    Bhattacharya, J. Quality Risk Management–Understanding and control the risk in pharmaceutical manufacturing industry. International Journal of Pharmaceutical Science Invention. 2015; 4(1): 29-41.
26.    Peter, F.G., Bernard, A.O., J. Pharm. Biomed Anal. 2008.
27.    Hardik Petal, Shraddha Parmar, Bhavna Patel, A Comprehensive Review on Quality by design in Pharmaceuticals, International Journal of Pharmaceutical Sciences Review and Research (Qbd), August 2013.
28.    Yu, Lawrence, pharmaceutical quality by design: Product and Process development, Understanding and Control. Pharmaceutical Research. 2008; 25(4)
29.    Trivedi, B. Quality by Desing (QbD) in Pharmaceuticals. Int J Pharm PharmSci. 2012; 4:17-29.
30.    Jain, S. Quality by design (QBD): a comprehensive understanding of implementation and challenges in pharmaceuticals development. Int. J. Pharm. Pharm. Sci. 2014; 6: 29-35
31.    Lawrence X.Y., Robert, L., Micheal, C Olson., Gary, B, Helen. Pharm. Technol. 2009; 33: 122.
32.    ICH Q8 (R2), Pharmaceutical Development, Part I: Pharmaceutical Development, (2009)
33.    ICH Q9, Quality Risk Management, (2005)
34.    Purohit, P.J. Shah, K.V. Quality By Design (Qbd): New Parameter For Quality Improvement and Pharmaceutical Drug Development, Pharma Science Monitor. Int J Pharm Sci. 2013;4: 1-19.
35.    Yu, Lawrence. Pharmaceutical quality by design: Product and Process development, Understanding and Control. Pharmaceutical Research. 2008; 25(4).
36.    Sharmista, Chatterjee, QbD Considerations for Analytical MethodsFDA Perspective, IFPAC Annual meeting, Baltimore, January 25, 2013.
37.    Priyanka P. Pande, Sadikali F. Sayyad, Machindra J. Chavan, Sanjay R. Chaudhari. Quality by design in analytical method development and validation.  Journal of Environmental and Life Science. 2017; 2(2).
38.    Jaiprakash N, Sangshetti, Mrinmayee Deshpande, Zahid Zaheer. Quality by design approach: Regulatory need. Aradian Journal of Chemistry Review. 2014.
39.    Mayur Ashok Chordiya, Hemant Hiraman Gangurde, Vikram Nirmal Sancheti, Quality by Design: A Roadmap for Quality Pharmaceutical Products. Journal of Reports in Pharmaceutical Sciences. 2019; 8(2): 289-294.
40.    Sachin L. Darkunde. A review on quality by design. International Journal of Pharmaceutical Chemistry and Analysis. 2018; 5(1): 1-6.
41.    P. J. Purohit, K. V. Shah. Quality By Design (Qbd): New Parameter For Quality Improvement and Pharmaceutical Drug Development. 2013; 4(3): 12-23.
42.    Lawrence X. Yu, Robert A. Lionberger, Sau Lawrence Lee, LaiMing Lee, Andre Raw Quality by Design: Concepts for ANDAs. The AAPS Journal. 2008; 10(2): 268-276.
43.    Determining Criticality-Process Parameters and Quality Attributes (2013) Bio Pharm International. 2013; 26(12): 13-18.
44.    Rathore AS, Winkle H () Quality by design for biopharmaceuticals. Nature Biotechnology. 2009; 27: 26-34.
45.    FDA CDER. Guidance for industry. Pharmaceutical Development. May 2006
46.    Bezerra MA, Santelli RE, Oliveira EP, Villar LS, Escaleira LA. Response surface methodology (RSM) as a tool for optimization in analytical chemistry. Talanta. 2008; 76(5):965-977.
47.    Candioti LV, De Zan MM, Cámara MS, Goichoechea HC. Experimental design and multiple response optimization. Using the desirability function in analytical methods development. Talanta. 2014; 124: 123-138.
48.    Politis SN, Colombo P, Colombo G, Rekkas DM. Design of experiments (DoE) in pharmaceutical development. Drug Develop Ind Pharm. 2017; 43(6):889-901
49.    Yu LX, Amidon G, Khan MA, Hoag SW, Polli J, Raju GK, Woodcock J. Understanding Pharmaceutical Quality by Design. AAPS J. 2014; 16(4): 771-783.
50.    Bhutani H, Kurmi M, Singh S, Beg S, Singh B. Quality by design (QbD) in analytical sciences: an overview. Pharma Times. 2014; 46(8): 71-75.
51.    Jadhav JB, Girawale NN, Chaudhari RA. Quality by Design (QbD): Approach used in Development of Pharmaceuticals. Int J Pure App Biosci 2014; 2(5): 214-223.
52.    Mayur Ashok Chordiya, Hemant Hiraman Gangurde, Vikram Nirmal Sancheti, Quality by Design: A Roadmap for Quality Pharmaceutical Products. Journal of Reports in Pharmaceutical Sciences. 2019; 8(2): 289-294.
53.    Gawade A, Chemate S, Kuchekar A. Pharmaceutical Quality by Design: A New Approach in Product Development. Res Rev J Pharm Pharm Sci. 2013; 2: 5- 12
54.    Purohit PJ, Shah KV. Quality By Design (Qbd): New Parameter For Quality Improvement and Pharmaceutical Drug Development. Int J Pharm Sci. 2013; 4: 1-19.
55.    Elder D P, Borman P. Improving analytical method reliability across the entire product lifecycle using QbD approaches. Pharmaceutical Outsourcing. 2013.


Recomonded Articles:

Author(s): Dipti G. Phadtare, Pawar Amol R, R.B. Saudagar

DOI: 10.5958/2231-5675.2016.00019.3         Access: Closed Access Read More

Author(s): Pankaj Bhamare, Rupal Dubey, Neeraj Upmanyu, Pothuvan Umadoss

DOI: 10.5958/2231-5675.2021.00001.6         Access: Open Access Read More

Author(s): Hamid Khan, Javed Ali

DOI: 10.5958/2231-5675.2017.00020.5         Access: Open Access Read More

Author(s): G. Krishnamoorthy, C. Diana Priyadarshini, R. Senthamarai

DOI:         Access: Open Access Read More

Author(s): Shobha Rani G, Lohita M, Jaya Preethi P, Madhavi R, Sunisitha B, Mounika D

DOI:         Access: Open Access Read More

Author(s): Kirthi A, Shanmugam R, Mohana Lakshmi S , Ashok Kumar CK, Padmini K, Shanti Prathyusha M, Shilpa V

DOI:         Access: Open Access Read More

Author(s): Mansi J. Chaudhari, Suraj R. Chaudhari, Shailesh S. Chalikwar, Atul A. Shirkhedkar

DOI: 10.5958/2231-5675.2018.00008.X         Access: Open Access Read More

Author(s): Khushboo Patel*, Dhara Patel, Jaya Dwivedi, Priyanka Newal, Dhananjay Meshram

DOI: 10.5958/2231-5675.2017.00039.4         Access: Open Access Read More

Author(s): Saroj Kumar Raul, Gopal Krishna Padhy, Pramudula Ramya Krishna, Boddu Uma Madhu Priya

DOI:         Access: Open Access Read More

Author(s): Saroj Kumar Raul, Bukkuru Spandana, Patibandla Sameera, Vegiraju Vikitha

DOI:         Access: Open Access Read More

Author(s): P. Janaki Pathi, N. Appala Raju, G.Parvathalu

DOI:         Access: Open Access Read More

Author(s): Paras Virani, Rajanit Sojitra, Hasumati Raj, Vineet Jain

DOI: 10.5958/2231-5675.2015.00025.3         Access: Open Access Read More

Author(s): B. Thangabalan, M. Salomi, N. Sunitha, S. Manohar Babu

DOI:         Access: Open Access Read More

Author(s): S. Subramanya Raj Urs, Bindu M., Ramyashree D., Sowmya K. N.

DOI: 10.5958/2231-5675.2020.00034.4         Access: Open Access Read More

Asian Journal of Pharmaceutical Analysis (AJPA) is an international, peer-reviewed journal, devoted to pharmaceutical analysis...... Read more >>>

RNI: Not Available                     
DOI: 10.5958/2231–5675 


Recent Articles




Tags